Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib

Understanding the genetic mechanisms of sensitivity to targeted anticancer therapies may improve patient selection, response to therapy, and rational treatment designs. One approach to increase this understanding involves detailed studies of exceptional responders: rare patients with unexpected exqu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wagle, Nikhil, Grabiner, Brian C., Van Allen, Eliezer M., Hodis, Eran, Jacobus, Susanna, Supko, Jeffrey G., Stewart, Michelle, Choueiri, Toni K., Gandhi, Leena, Cleary, James M., Elfiky, Aymen A., Taplin, Mary Ellen, Stack, Edward C., Signoretti, Sabina, Loda, Massimo, Shapiro, Geoffrey I., Sabatini, David, Lander, Eric S., Gabriel, Stacey B., Kantoff, Philip W., Garraway, Levi A., Rosenberg, Jonathan E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4122326/
https://ncbi.nlm.nih.gov/pubmed/24625776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0353
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak